Pide INAI publicar lista de medicamentos falsificados

The National Institute for Transparency, Access to Information and Personal Data Protection (INAI) ordered Mexico’s health regulatory authority, COFEPRIS, to disclose data on the most frequently counterfeited medications. This decision resolves a dispute in which the commission initially withheld requested transparency regarding health complaints and falsified drugs, prioritizing institutional secrecy over the public’s right to know. Open data serves as a critical tool for safeguarding public health by ensuring transparency in the pharmaceutical supply chain. When agencies publish verified information on risks, citizens can make informed decisions, effectively bridging the gap between regulatory oversight and individual safety. Ultimately, this case highlights that mandatory data release is essential for accountability. It reinforces the principle that access to health-related statistics empowers users to protect themselves, demonstrating how open data policies directly contribute to better health outcomes and trust in public institutions.

Source: cuartopoder.mx
Published on 2024-10-16